In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

The mRNA technology faces growing doubts among Republicans, including people around President Donald Trump. Legislation aimed to ban or limit mRNA vaccines was introduced this year by GOP lawmakers in ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

Now the nation’s top health official, Kennedy is reevaluating the US Health and Human Services’s contract with Moderna, which ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

The court ordered BNTX and PFE to furnish information about the revenue that it generated from selling their mRNA vaccine, Comirnaty. Moderna is seeking damages based on all sales of Comirnaty ...

But those calling for a ban on all mRNA vaccines say there is a dearth of long-term safety data, and they say covid vaccines by Pfizer-BioNTech and Moderna were hastily approved without proper ...